Aristides Capital’s KALA BIO KALA Stock Holding History

Aristides Capital’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10	Closed	-$176K	–	144
2020 Q4	$176K	Buy	+10	New	+$188K	0.06%	140

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristides Capital's KALA Position: Q1 2021 in Review

Aristides Capital sold out of KALA BIO (KALA) in Q1 2021, closing a stake of 10 shares — an estimated $176K sold.

Aristides Capital first reported a position in KALA in Q4 2020 and held it in 1 quarter. The position peaked at $176K in Q4 2020. 106 funds tracked by Wall St. Rank hold KALA as of Q1 2021.

Aristides Capital reported no remaining KALA BIO position as of Q1 2021 after selling out during the quarter.
Aristides Capital sold 10 KALA BIO shares in Q1 2021, an estimated $176K.
Aristides Capital first reported a position in KALA BIO in Q4 2020 and held it in 1 quarter.
Aristides Capital's KALA BIO position peaked at $176K in Q4 2020.
106 funds tracked by Wall St. Rank held KALA BIO as of Q1 2021.

Based on Aristides Capital's 13F filing for Q1 2021, filed 17 May 2021.